On Wednesday, the U.S. Food and Drug Administration (FDA) posted a letter on its Website warning Procter & Gamble (P&G) about issues with ingredients in its NyQuil and DayQuil cold products marketed under the Vicks brand. The warning letter has since been removed and the FDA said it was posted in error and was not sent to P&G.
The FDA’s site stated: “Yesterday, a warning letter to Procter & Gamble regarding Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C products was posted to the FDA Web site in error. The posting occurred due to an internal systems error, and no warning letter has been sent to Procter & Gamble. The agency regrets any confusion caused by the posting.”
MedPageToday noted that, originally, the issue concerned P&G listing vitamin C as an inactive ingredient in the medications and that the vitamin is not among the FDA’s listing of ingredients approved for combining with other medications in the NyQuil and DayQuil products.
The FDA said it would not be issuing any other comments; the letter did not state if the agency remains concerned about the vitamin C labeling on and, inclusion in, these products, said MedPageToday.
<You can skip to the end and leave a response. Pinging is currently not allowed.
